ClinicalTrials.gg
RecruitingNCT05442827Updated Jan 24, 2024

A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

A Phase 2/3 interventional study of SHR7280 tablets and SHR7280 tablets in Uterine Fibroids With Menorrhagia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
357
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Leiomyoma with a site in China — 19 open to participants now, 22 under way, 2 of them phase 3. Leiomyoma · China.

Planned enrollment
7th of 28
357 · median 160
Started
2022
with 3 others
Phase 2/3
2 of 39
1 open now
Primary completion
2026-06
later than 9 of 21 live
Registered
14th of 39
by date
Lead sponsor
4 of 39
Jiangsu HengRui Medicine Co., Ltd.

Among the 39 studies in Leiomyoma with a site in China, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 2/3, reaches primary completion later than 9 of the 21 other live ones, and was the 14th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

19 of the 39 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Leiomyoma with a site in China, or all of them as a file.
02

Study summary

Phase II:To explore the optimal effective dose of SHR7280 tablets in subjects with menorrhagia with uterine fibroids as a phase III treatment dose.

Phase III:To evaluate the efficacy of the selected dose of SHR7280 compared with placebo in reducing menstrual bleeding in subjects with menorrhagic uterine fibroids in phase II studies.

03

Conditions studied

  • Uterine Fibroids With Menorrhagia
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The has been signed and dated;
  2. Non-menopausal women between the ages of 18 and 49 (including 18 and 49);
  3. Single or multiple uterine fibroids were confirmed by ultrasound examination during screening, and the maximum diameter of at least one fibroid was ≥2 cm;
  4. Heavy menstrual bleeding measured by the alkaline hematin method during screening;
  5. 3 months before screening, the subject's menstrual cycle is 21-38 days, and the period is no more than 14 days;
  6. The pregnancy test was negative on the day of screening visit and randomization;
  7. Human papillomavirus (HPV) testing should be added for subjects who have cervical cytology at the time of screening visit and whose TCT results are atypical squamous cells (ASC-US) of uncertain significance, or who test negative for high-risk HPV.

Exclusion criteria

Exclusion Criteria:

  1. Excessive menstrual bleeding and anemia caused by other reasons;
  2. A history of depression or depression;
  3. Have a history of drug abuse, drug dependence;
  4. History of smoking and alcohol abuse within 3 months prior to screening;
  5. A history of delivery, breastfeeding and miscarriage within 6 months prior to screening;
  6. Patients who received myomectomy within 3 months before screening, and patients who received uterine artery embolization, or high intensity focused ultrasound (HIFU) ablation within 6 months before screening;
  7. Patients who underwent endometrial resection within 1 year prior to screening;
  8. Patients with severe infection (one organ or whole body infection caused by pathogenic microorganism, and failure or death of the organ or multiple organs caused by infection), severe trauma (ISS ≥16 points) or major surgery (grade III/IV surgery in Surgical Classification Catalogue) within 6 months prior to screening;
  9. Previous clinical major systemic disease, endocrine or metabolic abnormalities;
  10. Having past or current thromboembolic disease or having a risk factor for thromboembolic disease (stage 2 only);
  11. Previous history of malignant tumors such as ovary, breast, uterus, liver, hypothalamus and pituitary gland;Known or suspected sex hormone-dependent ;
  12. Any pre-existing disease or symptom (e.g., chronic intestinal disease, Crohn's disease, ulcerative colitis) that may affect systemic functioning of the body and may affect absorption, excessive accumulation, metabolism, or change the excretion pattern of the test drug;
  13. Persons with prior known serious mental illness or inability to understand the purpose, methods, etc. of the clinical trial, and who did not follow the study procedures;
  14. Live (attenuated) vaccine (other than influenza vaccine) received within 1 month prior to screening or planned during the trial;
  15. Other reasons that the investigator considered inappropriate for participation in the study.
  16. Follicle-stimulating hormone (FSH) ≥25U/L during screening;
  17. \< 6 g/dL during screening;
  18. Moderate to severe liver impairment during screening, including (AST), alanine aminotransferase (ALT), or (unless Gilbert's diagnosis is known) ≥2.0 times the upper limit of the reference range;
  19. During screening, endometrial should be performed if endometrial thickness > 18 mm is indicated by gynecological ultrasound or if the investigator deems it necessary. Endometrial histological abnormalities indicated by endometrial biopsy should be performed (only in the first stage).
  20. Active pelvic inflammatory disease (PID) during screening;
  21. ≥450ms during screening;
  22. Infectious disease screening resultshave clinical significance;
  23. 6 months before enrollment, endometrial biopsy revealed significant endometrial histological abnormalities;If the subject has no sexual life history or the investigator determines that it is not necessary, the subject may be exempted (stage 2 only);
  24. Two or more blood transfusions within 9 months prior to enrollment, or requiring transfusion therapy within 2 months prior to enrollment, or having any condition requiring immediate transfusion;
  25. 1 month before admission, she used any drugs that inhibited or induced liver metabolism of drugs (liver drug enzyme inhibitors such as chloramphenicol, allopurinol,ketoconazole, fluoroquinolones, etc., and liver drug enzyme inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin sodium, rifamequine);
  26. Participants in and enrolled in clinical trials of any drug or medical device within 3 months prior to enrollment, or who were still in the follow-up period of a clinical study or within 5 half-lives of the tested drug prior to screening, whichever is longer.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
357 participants (estimated)

Study arms

  • Experimental
    Treatment group A: SHR7280 tablets

    Drug: SHR7280 tablets

  • Experimental
    Treatment group B:SHR7280 tablets

    Drug: SHR7280 tablets

  • Placebo comparator
    Treatment group C:Intervention: Drug: PlaceboSHR7280 tablets blank preparation

    Drug: PlaceboSHR7280 tablets blank preparation

Interventions

  • SHR7280 tablets 300mg for 12 weeks

  • SHR7280 tablets 400mg for 12 weeks

  • DrugPlaceboSHR7280 tablets blank preparation

    Placebo group: SHR7280 tablets blank preparation for 12 weeks

06

What researchers measure

Primary outcomes

  1. Phase one:Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline

    Time frame: After treatment at week 12

  2. Phase two:Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline

    Time frame: After treatment at week 24

Secondary outcomes

  1. Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline(Phase one)

    Time frame: The treatment ended at week 4 and 8

  2. percentage of subjects without menstrual bleeding or spotting (Phase one)

    Time frame: The treatment ended at week 4, 8 and 12

  3. Changes in hemoglobin concentration from baseline(Phase one)

    Time frame: The treatment ended at week 4, 8 and 12

  4. Changes in uterine volume and maximum fibroid volume from baseline(Phase one)

    Time frame: The treatment ended at week 8 and 12

  5. patient global impression of change scale evaluation,The minimum is 1, the maximum is 7, and higher scores mean worse results(Phase one)

    Time frame: The treatment ended at week 12

  6. Changes in uterine fibroid symptoms from baseline(Phase one)

    Time frame: The treatment ended at week 12

  7. Changes in health related Quality of Life Questionnaire (UFS-QOL) scores from baseline,The minimum is 37 and the maximum is 185, with higher scores indicating worse results(Phase one)

    Time frame: The treatment ended at week 12

  8. Number of Participants with Adverse events(Phase one)

    Time frame: Stage ⅱ ended, about 30 weeks

  9. The interval between stopping the medication and resuming menstruation(Phase one)

    Time frame: Stage ⅱ ended, about 30 weeks

  10. The amount of menstrual bleeding when the medication was stopped until menstruation resumed(Phase one)

    Time frame: Stage ⅱ ended, about 30 weeks

  11. Number of days of menstruation from the time of discontinuation of the medication to the time of resumption of menstruation(Phase one)

    Time frame: Stage ⅱ ended, about 30 weeks

  12. SHR7280 concentration in plasma(Phase one)

    Time frame: Before and at week 4, 8 and 12 after administration

  13. Serum concentrations of estradiol, luteinizing hormone, follicle stimulating hormone and progesterone(Phase one)

    Time frame: Before and at week 4, 8 and 12 after administration

  14. Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline(Phase two)

    Time frame: At the end of weeks 4,8,12,16,20,28,32,36,40,44,48,52

  15. Changes in menstrual bleeding from baseline were assessed using the Alkaline hematin method (AH)(Phase two)

    Time frame: At the end of weeks 4,8,12,16,20,24,28,32,36,40,44,48,52

  16. percentage of subjects without menstrual bleeding or spotting (Phase two)

    Time frame: Weeks 4,8,12,16,20,24,28,32,36,40,44,48,52

  17. change in Hb concentration from baseline (Phase two)

    Time frame: The treatment ended at 4, 8, 12, 16, 20, 24, 36, 44, 52 weeks

  18. Changes in uterine volume and maximum fibroid volume from baseline(Phase two)

    Time frame: The treatment ended at weeks 12, 24, and 52

  19. patient global impression of change scale evaluation,The minimum is 1, the maximum is 7, and higher scores mean worse results(Phase two)

    Time frame: The treatment ended at weeks 12, 24, and 52

  20. Changes in health related Quality of Life Questionnaire (UFS-QOL) scores from baseline,The minimum is 37 and the maximum is 185, with higher scores indicating worse results(Phase two)

    Time frame: The treatment ended at weeks 12, 24, and 52

  21. Number of Participants with Adverse events(Phase two)

    Time frame: Stage ⅲ ended at about 74 weeks

  22. The interval between stopping the medication and resuming menstruation(Phase two)

    Time frame: Stage ⅲ ended at about 74 weeks

  23. The amount of menstrual bleeding when the medication was stopped until menstruation resumed(Phase two)

    Time frame: Stage ⅲ ended at about 74 weeks

  24. Number of days of menstruation from the time of discontinuation of the medication to the time of resumption of menstruation(Phase two)

    Time frame: Stage ⅲ ended at about 74 weeks

  25. plasma SHR7280 concentration data(Phase two)

    Time frame: Treatment ended at 4, 24, 36, 52 weeks before administration

  26. serum E2, LH, FSH and P concentrations at each point of view(Phase two)

    Time frame: Treatment was completed at 4, 8, 12, 16, 20, 24, 36, 44, 52 weeks before administration

07

Study locations

1 of 1 sites recruiting
  • Peking University First Hospital
    Beijing, Beijing 100034, China
    Recruiting
    • Yingfang Zhou · Principal investigator
    • Chao Peng · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jun 2026, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Jul 5, 2022
StartActual
Sep 10, 2022
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05442827
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Sep 10, 2022
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Jan 24, 2024

Study contacts

Zhenyi Zhu
Contact
zhenyi.zhu@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GnRH Antagonist SHR7280

Start the discussion